IP1867B is a potential brain cancer treatment under development by for use in the treatment of brain tumors, by combining reformulated aspirin with two additional ingredients, into a soluble form. Developing a true liquid aspirin has long been a scientific goal. This new formulation significantly increases the ability of drugs to cross the blood brain barrier, which serves to protect the brain but also blocks many conventional cancer drugs from reaching brain tumors.
Property | Value |
---|---|
dbo:abstract |
|
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink | |
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |